adsb-fub-187 adsb-fub-187 adsb-fub-187 is an indazole-based synthetic cannabinoid. it is a potent agonist of the cb1 receptor with a binding affinity of ki = 0.09 nm and an ec50 of 1.09 nm. it was originally developed by pfizer in 2009, being example 187 from patent wo 2009/106982. while it is the most tightly binding compound from this patent in terms of ki, it is not the most potent compound at producing a cb1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower ec50 values. adsb-fub-187legal statuslegal status ca: schedule ii de: npsg (industrial and scientific use only) uk: under psychoactive substances act identifiers iupac name 7-chloro-n--3,3-dimethyl-1-oxobutan-2-yl]-1-indazole-3-carboxamide cas number1185283-97-9 ypubchem cid44186812chemspider65322246uniil6k9pbl5eochemical and physical dataformulac26h31clfn5o4smolar mass564.07 g·mol−13d model (jsmol)interactive image smiles cc(c)(c)(c(=o)nccns(=o)(=o)c1cc1)nc(=o)c2=nn(c3=c2c=cc=c3cl)cc4=cc=c(c=c4)f inchi inchi=1s/c26h31clfn5o4s/c1-26(2,3)23(25(35)29-13-14-30-38(36,37)18-11-12-18)31-24(34)21-19-5-4-6-20(27)22(19)33(32-21)15-16-7-9-17(28)10-8-16/h4-10,18,23,30h,11-15h2,1-3h3,(h,29,35)(h,31,34)/t23-/m1/s1key:uanjtrhqsbhcid-hszrjfapsa-n legality sweden's public health agency suggested classifying adsb-fub-187 as hazardous substance on november 10, 2014, following its use as an ingredient in grey-market synthetic cannabis products.